Navigation Links
Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
Date:9/24/2009

SAN DIEGO, Calif., INDIANAPOLIS, Ind., and CAMBRIDGE, Mass., Sept. 24, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) will unveil data from more than 20 studies at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, taking place from Sept. 29 to Oct. 2. The companies will present the latest research findings on BYETTA(R) (exenatide) injection and exenatide once weekly. The EASD annual meeting, which brings together more than 14,000 delegates, is the most important platform in Europe for professional exchange in the diabetes field.

"The presentations at EASD continue to reinforce the efficacy and safety of BYETTA and the promise of exenatide once weekly as a potential new treatment option for patients with type 2 diabetes," stated Orville G. Kolterman, M.D., senior vice president of research and development, Amylin Pharmaceuticals. "EASD is a venue where researchers and clinical practitioners from around the world gather to discuss new developments in diabetes care. We look forward to participating in this exchange of ideas by presenting compelling data on the exenatide molecule."

Key exenatide abstracts for EASD 2009 include:

Clinical Trial Data

  • Poster: Presentation #729, Sept. 30, 1:45-2:45 p.m. CEST "Effects of Exenatide plus Rosiglitazone on Measures of Beta Cell Function and Insulin Sensitivity in Subjects with
    '/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
2. Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
3. Amylin Pharmaceuticals to Webcast Second Quarter Results
4. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
5. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
6. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
7. Amylin Announces Preliminary Tabulation of Annual Meeting Results
8. Amylin Responds to Eastbourne Letter
9. Amylin Comments on RiskMetrics Report
10. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
11. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... The College of New Rochelle announced today ... Mid-Hudson Region to be designated as a START-UP NY ... qualified “high-technology” businesses that align with the College’s academic ... been selected for the START-UP NY program and extremely ... economic development in New York by growing business and ...
(Date:8/21/2014)... Calif. , Aug. 21, 2014  Four-dimensional ... and behaviors based on external stimuli such as ... to have a disruptive effect in multiple industries.  ... the business landscape by printing objects ranging from ... and automotive sectors. Logo - ...
(Date:8/21/2014)... On Wednesday of last week RENU 28, the world's ... became available for purchase in Australia and New Zealand, and ... 28 works is, if you think about the definition of ... cellular renewal within your body. If you think about the ... cellular renewal. What RENU 28 does is it works with ...
(Date:8/20/2014)... PLANTATION, Fla. , Aug. 20, 2014 /PRNewswire/ ... it will host a conference call to provide ... 26, 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 ... number: 9126599 Live web cast: www.neurotropebioscience.com , under ... three hours after completion through September 2, 2014 ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2
... Diagnostics (NYSE: DGX ), the world,s leading ... that the U.S. Food and Drug Administration (FDA) has ... its STRATIFY JCV ™ Antibody ELISA testing service. ... FDA market authorized for the qualitative detection of antibodies ...
... have new hope in a novel technology now offered ... Case Medical Center.  A team of cancer specialists, led ... the nation to launch a dedicated program using Hyperthermic ... other cancers. Performed immediately following surgery, HIPEC ...
... Calif., Jan. 20, 2012  Genomic Health, Inc. (Nasdaq: ... first clinical decision making study of the Onco type ... Score® (RS) result has a significant impact on treatment ... to be presented at the 2012 Gastrointestinal (GI) Cancers ...
Cached Biology Technology:Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients 2Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients 3UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients 2UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients 3Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 2Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 3Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 4Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 5Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 6
(Date:8/21/2014)... in past decade, GTA still violates Canada,s ozone ... the Greater Toronto Area (GTA) has significantly reduced ... the city continues to violate the Canada-wide standards ... or aggravate health problems such as asthma, emphysema ... of complex photochemical reactions involving volatile organic compounds ...
(Date:8/21/2014)... growing in near darkness use a previously unknown process ... research team led by a Penn State University scientist ... research aimed at improving plant growth, harvesting energy from ... occurring on Lake Erie and other lakes worldwide. A ... Science Express edition of the journal ...
(Date:8/21/2014)... 21, 2014 /PRNewswire-iReach/ -- LiveScan Service Provider  ... to a partnership with Gabriel Health Institute, one ... growing Certified Nursing Assistant preparatory schools. The ... exclusive member of Binary,s LiveScan service provider,s owner/operator ... improve its service capabilities by widening the ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3
... 22, 2010 -- What can scientists learn from watching ... reading, and happily making new friends? Quite a lot, ... carefully observed this sort of group in a fatigue ... in The Journal of the Acoustical Society of America. ...
... team of researchers led by Carnegie Mellon University,s Manojkumar ... recycle, a critical piece in understanding signaling receptor function. ... first time describes how a signaling receptor travels back ... and internalized. Signaling receptors live on the cell ...
... Researchers at Cleveland Clinic,s Genomic Medicine Institute have revealed multiple ... for Cowden syndrome patients who are predisposed to breast and ... earlier discovery of cancerous tumors, is published in the Dec. ... Association ( JAMA ). Charis Eng, M.D., ...
Cached Biology News:Measuring fatigue through the voice 2Carnegie Mellon researchers discover mechanism for signaling receptor recycling 2Carnegie Mellon researchers discover mechanism for signaling receptor recycling 3Researchers discover genetic predisposition for breast, kidney cancers 2
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Antibody Diluent for IHC 125 ml...
Quinolinate phosphoribosyltransferase...
JMJD2B Antibody...
Biology Products: